PMID- 34346940
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Print)
IS  - 0066-782X (Linking)
VI  - 117
IP  - 4
DP  - 2021 Oct
TI  - Increased, Decreased, or Stable Left Ventricle Ejection Fraction over Time in a 
      Series of 626 Heart Failure Patients Receiving Medical Treatment.
PG  - 639-647
LID - 10.36660/abc.20200250 [doi]
AB  - BACKGROUND: Ejection fraction (EF) has been used in phenotype analyses and to 
      make treatment decisions regarding heart failure (HF). Thus, EF has become a 
      fundamental part of daily clinical practice. OBJECTIVE: This study aims to 
      investigate the characteristics, predictors, and outcomes associated with EF 
      changes in patients with different types of severe HF. METHODS: A total of 626 
      severe HF patients with New York Heart Association (NYHA) class III-IV were 
      enrolled in this study. The patients were classified into three groups according 
      to EF changes, namely, increased EF (EF-I), defined as an EF increase >/=10%, 
      decreased EF (EF-D), defined as an EF decrease >/=10%, and stable EF (EF-S), 
      defined as an EF change <10%. A p-value lower than 0.05 was considered 
      significant. RESULTS: Out of 377 severe HF patients, 23.3% presented EF-I, 59.5% 
      presented EF-S, and 17.2% presented EF-D. The results further showed 68.2% of 
      heart failure with reduced ejection fraction (HFrEF) in the EF-I group and 64.6% 
      of heart failure with preserved ejection fraction (HFpEF) in the EF-D group. The 
      predictors of EF-I included younger age, absence of diabetes, and lower left 
      ventricular ejection fraction (LVEF). The predictors of EF-D were absence of 
      atrial fibrillation, lower uric acid level, and higher LVEF. Within a median 
      follow-up of 40 months, 44.8% of patients suffered from all-cause death. 
      CONCLUSION: In severe HF, HFrEF presented the highest percentage in the EF-I 
      group, and HFpEF was most common in the EF-D group.
FAU - Han, Meng-Meng
AU  - Han MM
AD  - Intensive Care Unit, Beijing Longfu Hospital, Beijing - China.
FAU - Zhao, Wen-Shu
AU  - Zhao WS
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Xu, Xiao-Rong
AU  - Xu XR
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Wang, Xin
AU  - Wang X
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Li, Kui-Bao
AU  - Li KB
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Dang, Cai-Jing
AU  - Dang CJ
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Zhang, Juan
AU  - Zhang J
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Liu, Jia-Mei
AU  - Liu JM
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Chen, Mu-Lei
AU  - Chen ML
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Yang, Xin-Chun
AU  - Yang XC
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Xu, Lin
AU  - Xu L
AUID- ORCID: 0000-0002-2043-7256
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
FAU - Wang, Hua
AU  - Wang H
AD  - Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing - China.
LA  - eng
LA  - por
PT  - Journal Article
TT  - Fracao de Ejecao do Ventriculo Esquerdo Aumentada, Diminuida ou Estavel ao Longo 
      do Tempo em uma Serie de 626 Pacientes com Insuficiencia Cardiaca que Receberam 
      Tratamento Medico.
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
SB  - IM
MH  - *Heart Failure/drug therapy
MH  - Heart Ventricles
MH  - Humans
MH  - Prognosis
MH  - Stroke Volume
MH  - Ventricular Function, Left
PMC - PMC8528370
OAB - BACKGROUND: Ejection fraction (EF) has been used in phenotype analyses and to 
      make treatment decisions regarding heart failure (HF). Thus, EF has become a 
      fundamental part of daily clinical practice. OBJECTIVE: This study aims to 
      investigate the characteristics, predictors, and outcomes associated with EF 
      changes in patients with different types of severe HF. METHODS: A total of 626 
      severe HF patients with New York Heart Association (NYHA) class III-IV were 
      enrolled in this study. The patients were classified into three groups according 
      to EF changes, namely, increased EF (EF-I), defined as an EF increase >/=10%, 
      decreased EF (EF-D), defined as an EF decrease >/=10%, and stable EF (EF-S), 
      defined as an EF change <10%. A p-value lower than 0.05 was considered 
      significant. RESULTS: Out of 377 severe HF patients, 23.3% presented EF-I, 59.5% 
      presented EF-S, and 17.2% presented EF-D. The results further showed 68.2% of 
      heart failure with reduced ejection fraction (HFrEF) in the EF-I group and 64.6% 
      of heart failure with preserved ejection fraction (HFpEF) in the EF-D group. The 
      predictors of EF-I included younger age, absence of diabetes, and lower left 
      ventricular ejection fraction (LVEF). The predictors of EF-D were absence of 
      atrial fibrillation, lower uric acid level, and higher LVEF. Within a median 
      follow-up of 40 months, 44.8% of patients suffered from all-cause death. 
      CONCLUSION: In severe HF, HFrEF presented the highest percentage in the EF-I 
      group, and HFpEF was most common in the EF-D group.
OABL- eng
COIS- Potencial conflito de interesse Nao ha conflito com o presente artigo
EDAT- 2021/08/05 06:00
MHDA- 2021/11/03 06:00
PMCR- 2021/07/21
CRDT- 2021/08/04 12:25
PHST- 2020/03/25 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2021/08/05 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/08/04 12:25 [entrez]
PHST- 2021/07/21 00:00 [pmc-release]
AID - S0066-782X2021005011201 [pii]
AID - abc.20200250 [pii]
AID - 10.36660/abc.20200250 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2021 Oct;117(4):639-647. doi: 10.36660/abc.20200250.